8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2009

MEDTOX SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-11394	95-3863205
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

Item 7.01.Regulation FD Disclosure

Attached as Exhibit 99.1 is a MEDTOX Scientific, Inc. corporate fact sheet that has been or may be given to investors beginning on October 29, 2009. This information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Item 8.01. Other Events

On October 30, 2009, MEDTOX Scientific, Inc. (the “Company”) was included in an article published by Minneapolis/St. Paul Business Journal. The article is attached as Exhibit 99.2.

The information in this Item 8.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

2

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

The following exhibit is furnished as part of this report:

ExhibitNo.	Description
99.1 99.2	MEDTOX Scientific, Inc. Corporate Fact Sheet dated October 29, 2009. Article published by Minneapolis/St. Paul Business Journal on October 30, 2009.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTOX Scientific, Inc.

Date: November 4, 2009 By:  /s/ Richard J. Braun

Name:     Richard J. Braun

Title: Chief Executive Officer

4

INDEX TO EXHIBITS

ExhibitNo.	Description
99.1 99.2	MEDTOX Scientific, Inc. Corporate Fact Sheet dated October 29, 2009. Article published by Minneapolis/St. Paul Business Journal on October 30, 2009.

5

EX-99

Exhibit 99.1

See Attached pdf file ex99-1102909.pdf.

EX-99

Exhibit 99.2

See Attached pdf file ex99-2102909.pdf.